US FDA Approves Ameluz Red-Light PDT for Superficial Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) has approved Biofrontera Inc.’s supplemental New Drug Application for Ameluz (aminolevulinic acid hydrochloride topical gel, 10%) in combination with photodynamic therapy using the BF-RhodoLED lamp series for the treatment of superficial basal cell carcinoma (sBCC) in adults. The approval expands the use of Ameluz into skin cancer treatment [...]








